Post by Biomed Industries Inc

Biomed Industries will be presenting Phase 2 data for NA-931, its oral quadruple receptor agonist, at the upcoming ObesityWeek conference, taking place November 4–7 in Atlanta. The Company is also presenting two scientific papers: Associations Between Alzheimer’s Disease (AD) and Obesity: Clinical Trials of NA-831 for AD and NA-931 for the Treatment of Obesity” — highlighting Biomed’s pioneering research that links neurodegenerative and metabolic disorders. And, Obesity Drugs Over the Past 20 Years – Trends and Future Directions: A Meta-Analysis of Clinical Trials Using ML and AI” — offering a comprehensive overview of the evolution of obesity therapeutics, from early GLP-1 agonists to next-generation multi-agonist strategies. Learn more at: https://lnkd.in/gmPBF4y8